

Abstract (Basic) : EP 465979 A

MAb (I) is capable of substantially neutralising HIV. It binds to a glycoprotein antigen, gp120 , (mwt. 12 x 104d) present in the envelope of HIV.

Also new are :- (1) a pharmaceutical composition contg. (I) or a fragment thereof in combination with a pharmaceutically acceptable carrier and/or diluent; (2) a diagnostic compsn. contg. (I); and (3) a test kit for HIV diagnosis, contg. (I) or fragments.

(I) is effective against a human T-lymphotropic virus IIIMN. In addition it has the following characteristics:- (a) it is of the IgGx class; (b) capable of recognising at least 1 epitope present in the region of the aminoacid sequence 303-32S (Tyr Asn Lys Arg Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Lys Asn Ile Ile Gly) of gp120 of HTLV-IIIMN; (c) can bind to the surface of HTLV-IIIMN viral particles and thereby inhibit infection of the viral particles to CD4-positive cells; and (d) produced by the hybridoma FERM BP.3402.

USE/ADVANTAGE - (I) can inhibit cell-to-cell infection e.g. syncytium formation and/or cell-free virus infection with HTLV-IIIMN. Used for prophylaxis and treatment of AIDS. (13pp Dwg.No.0